CHO Pharma, Inc. (TPEX:6586)

Market Cap	14.47B +60.6%
Revenue (ttm)	1.43M -60.0%
Net Income	-290.01M
EPS	-1.36
Shares Out	214.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	631,897
Open	64.10
Previous Close	64.80
Day's Range	64.10 - 70.60
52-Week Range	22.75 - 73.40
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About CHO Pharma

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 47
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6586

Financial Performance

In 2025, CHO Pharma's revenue was 1.43 million, a decrease of -60.03% compared to the previous year's 3.58 million. Losses were -290.01 million, 36.6% more than in 2024.